2-甲基-3,5,6,7-四氢-环戊并嘧啶-4-酮 | 65818-01-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 2-甲基-3,5,6,7-四氢-环戊并嘧啶-4-酮
• 英文名称: 2-methyl-6,7-dihydro-3H-cyclopenta[d]pyrimidin-4(5H)-one
• 英文别名: 2-methyl-3,5,6,7-tetrahydro-cyclopentapyrimidin-4-one；2-Methyl-3,5,6,7-tetrahydro-cyclopentapyrimidin-4-on；2-methyl-3,5,6,7-tetrahydrocyclopenta[d]pyrimidin-4-one
• CAS: 65818-01-1
• 化学式: C₈H₁₀N₂O
• 分子量: 150.18
• InChiKey: GPHGETSVSBZRQC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  41.5
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  2-甲基-3,5,6,7-四氢-环戊并嘧啶-4-酮 在 盐酸 、 三氯氧磷 作用下， 以 异丙醇 为溶剂， 反应 3.0h， 生成 N-(4-methoxyphenyl)-N,2-dimethyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-aminium chloride
  参考文献：
  名称：

  Structure–Activity Relationship and in Vitro and in Vivo Evaluation of the Potent Cytotoxic Anti-microtubule Agent N-(4-Methoxyphenyl)-N,2,6-trimethyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-aminium Chloride and Its Analogues As Antitumor Agents

  摘要：

  A series of 21 substituted cyclopenta[d]pyrimidines were synthesized as an extension of our discovery of the parent compound (+/-)-1 center dot HCl as an anti-microtubule agent. The structure activity relationship indicates that the N-methyl and a 4N-methoxy groups appear important for potent activity. In addition, the 6-substituent in the parent analogue is not necessary for activity. The most potent compound 30. HCl was a one to two digit nanomolar inhibitor of most tumor cell proliferations and was up to 7-fold more potent than the parent compound (+/-)-1 center dot HCl. In addition, 30 center dot HCl inhibited cancer cell proliferation regardless of Pgp or beta III-tubulin status, both of which are known to cause clinical resistance to several antitubulin agents. In vivo efficacy of 30 center dot HCl was demonstrated against a triple negative breast cancer xenograft mouse model. Compound 30 center dot HCl is water-soluble and easily synthesized and serves as a lead compound for further preclinical evaluation as an

  DOI：

  10.1021/jm400639z
• 作为产物：
  描述：

  盐酸乙脒 、 2-甲氧羰基环戊酮 在 potassium tert-butylate 作用下， 以 叔丁醇 为溶剂， 以81%的产率得到2-甲基-3,5,6,7-四氢-环戊并嘧啶-4-酮
  参考文献：
  名称：

  Structure–Activity Relationship and in Vitro and in Vivo Evaluation of the Potent Cytotoxic Anti-microtubule Agent N-(4-Methoxyphenyl)-N,2,6-trimethyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-aminium Chloride and Its Analogues As Antitumor Agents

  摘要：

  A series of 21 substituted cyclopenta[d]pyrimidines were synthesized as an extension of our discovery of the parent compound (+/-)-1 center dot HCl as an anti-microtubule agent. The structure activity relationship indicates that the N-methyl and a 4N-methoxy groups appear important for potent activity. In addition, the 6-substituent in the parent analogue is not necessary for activity. The most potent compound 30. HCl was a one to two digit nanomolar inhibitor of most tumor cell proliferations and was up to 7-fold more potent than the parent compound (+/-)-1 center dot HCl. In addition, 30 center dot HCl inhibited cancer cell proliferation regardless of Pgp or beta III-tubulin status, both of which are known to cause clinical resistance to several antitubulin agents. In vivo efficacy of 30 center dot HCl was demonstrated against a triple negative breast cancer xenograft mouse model. Compound 30 center dot HCl is water-soluble and easily synthesized and serves as a lead compound for further preclinical evaluation as an

  DOI：

  10.1021/jm400639z

文献信息

• [EN] HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF<br/>[FR] COMPOSÉS HÉTÉROARYLES ET PROCÉDÉ D'UTILISATION CORRESPONDANT
  申请人：SUNOVION PHARMACEUTICALS INC

  公开号：WO2013119895A1

  公开（公告）日：2013-08-15

  Provided herein are thiophene compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders, including but not limited to, psychosis and schizophrenia.

  本文提供了噻吩化合物，其合成方法，包含这些化合物的药物组合物，以及它们的使用方法。本文提供的化合物可用于治疗、预防和/或管理各种神经系统疾病，包括但不限于精神病和精神分裂症。
• Cyclopenta[d]pyrimidines And Substituted Cyclopenta[d]pyrimidines As Antitubulin and Microtubule Targeting Agents, Monocyclic Pyrimidines As Tubulin Inhibitors, And Pyrrolopyrimidines As Targeted Antifolates And Tubulin and Multiple Receptor Tyrosine Kinase Inhibition And Antitumor Agents
  申请人：Duquesne University of the Holy Spirit

  公开号：US20160304525A1

  公开（公告）日：2016-10-20

  The present invention provides a compound of Formula I, and salts thereof, and a pharmaceutical composition comprising a compound of Formula I: wherein R 1 is selected from the group consisting of and R 2 is an alkyl group having from one to ten carbon atoms, or wherein R 2 is selected from the group consisting of R 1 is an alkyl group having from one to ten carbon atoms; and R is H, or an alkyl group having from one to ten carbon atoms, and R 3 is H, an alkyl group having from one to ten carbon atoms, or a halogen. Preferably the compound of Formula V includes wherein R 3 is a halogen, and most preferably wherein the halogen is chlorine. Methods of treating a patient with cancer with these compounds are also provided.

  本发明提供了一种化合物I的盐，以及包括化合物I的药物组合物：其中R1选自以下组成的群体，R2是具有一到十个碳原子的烷基基团，或者R2选自以下组成的群体，R1是具有一到十个碳原子的烷基基团；R是H，或者具有一到十个碳原子的烷基基团，R3是H，具有一到十个碳原子的烷基基团，或者卤素。优选化合物V包括其中R3是卤素，最优选其中卤素是氯。还提供了使用这些化合物治疗癌症患者的方法。
• [EN] SUBSTITUTED PYRIMIDINE COMPOUNDS AND METHODS OF USE AND MANUFACTURE<br/>[FR] COMPOSÉS DE PYRIMIDINE SUBSTITUÉE ET LEURS PROCÉDÉS D'UTILISATION ET DE FABRICATION
  申请人：UNIV HOLY GHOST DUQUESNE

  公开号：WO2016022881A1

  公开（公告）日：2016-02-11

  This invention provides substituted pyrimidine compounds that are useful in treating a patient having a disease or cancer. The compounds of this invention are useful as multi-enzyme antifolates selectively targeting the folate receptor (FR). Further, a method of making 5-and 6-substituted cyclopenta[d]pyrimidine for nonclassical and classical antifolates as TS and DHFR inhibitors is provided.

  本发明提供了可用于治疗患有疾病或癌症的取代嘧啶化合物。本发明的化合物可用作多酶抗叶酸类药物，选择性地靶向叶酸受体（FR）。此外，还提供了一种制备5-和6-取代环戊[d]嘧啶的方法，用于非经典和经典抗叶酸类药物，作为TS和DHFR抑制剂。
• Heteroaryl Compounds and Methods of Use Thereof
  申请人：Sunovion Pharmaceuticals, Inc.

  公开号：US20150031709A1

  公开（公告）日：2015-01-29

  Provided herein are thiophene compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders, including but not limited to, psychosis and schizophrenia.

  本文提供了噻吩化合物、它们的合成方法、包含这些化合物的药物组合物以及使用这些化合物的方法。这些化合物对于治疗、预防和/或管理各种神经系统疾病，包括但不限于精神病和精神分裂症，具有实用性。
• Substituted Pyrimidine Compounds and Methods of Use and Manufacture
  申请人：Duquesne University of the Holy Spirit

  公开号：US20160039830A1

  公开（公告）日：2016-02-11

  This invention provides substituted pyrimidine compounds having the formula: wherein X is absent, CH 2 , S, or O, and R is an alkyl group having from one to ten carbon atoms, and optionally salts, hydrates, or solvates thereof, that are useful in treating a patient having a disease or cancer. The compounds of this invention are useful as multi-enzyme antifolates selectively targeting the folate receptor (FR). Further, a method of making 5- and 6-substituted cyclopenta[d]pyrimidine for nonclassical and classical antifolates as TS and DHFR inhibitors is provided.

  本发明提供了具有以下式子的取代嘧啶化合物：其中X为不存在，CH2，S或O，而R是具有从一到十个碳原子的烷基，以及其可选的盐、水合物或溶剂化物，这些化合物在治疗患有疾病或癌症的患者方面是有用的。本发明的化合物可用作多酶抗叶酸剂，有选择性地靶向叶酸受体（FR）。此外，本发明还提供了一种制备5-和6-取代环戊[d]嘧啶用于非经典和经典抗叶酸剂作为TS和DHFR抑制剂的方法。